Assessment of Diagnostic Utility of Serum Hemeoxygenase-1 Measurement for Acute Exacerbation of Interstitial Pneumonias

Overview

Journal Sci Rep

Specialty Science

Date 2022 Jul 28

PMID 35902685

Authors

Yuki Kata

Yu Hara

Yoichi Tagami

Aya Yabe

Kota Murohashi

Ryo Nagasawa

Kentaro Nakashima

Hiroaki Fujii

Yusuke Saigusa

Masafumi Shiida

Keisuke Watanabe

Nobuyuki Horita

Nobuaki Kobayashi

Takeshi Kaneko

Affiliations

Soon will be listed here.

Abstract

The present study aimed to evaluate whether serum heme oxygenase (HO)-1 could be a reliable blood biomarker for diagnosing acute exacerbations (AEs) of both idiopathic interstitial pneumonia (IIP) and secondary interstitial pneumonia (SIP). Serum HO-1 levels of newly diagnosed patients with IP were measured, and the relationships between serum HO-1 and other serum biomarkers and high-resolution CT scores, were evaluated. Blood samples were collected from 90 patients with IIP, including 32 having an AE, and 32 with SIP, including 9 having an AE. The patients having an AE had significantly higher HO-1 levels than those not having an AE (35.2 ng/mL vs. 16.4 ng/mL; p < 0.001). On receiver operating characteristics (ROC) curve analysis for serum HO-1 ability to detect an AE, the area under the ROC curve (AUC) was 0.87 in patients with IIPs and 0.86 in those with SIPs. Also, in patients with both IIPs and SIPs, the combination of the serum HO-1 level and the GGO score showed favorable AUCs (IIPs: 0.92, SIPs: 0.83), though HO-1-not-including model (combination of LDH and GGO) also showed acceptable AUCs. Serum HO-1 could be a clinically useful biomarker for the accurate diagnosis of patients with AEs.

Citing Articles

Serum surfactant protein D as a significant biomarker for predicting occurrence, progression, acute exacerbation, and mortality in interstitial lung disease: a systematic review and meta-analysis.

He X, Ji J, Zheng D, Luo Z, Luo L, Guo L Front Immunol. 2025; 16:1450798.

PMID: 40028331 PMC: 11868069. DOI: 10.3389/fimmu.2025.1450798.

Serum heme oxygenase-1 as a prognostic biomarker in patients with acute exacerbation of interstitial lung disease.

Tagami Y, Hara Y, Murohashi K, Nagasawa R, Fujii H, Izawa A Sci Rep. 2023; 13(1):22639.

PMID: 38114539 PMC: 10730846. DOI: 10.1038/s41598-023-49342-4.

References

Oda K, Ishimoto H, Yamada S, Kushima H, Ishii H, Imanaga T . Autopsy analyses in acute exacerbation of idiopathic pulmonary fibrosis. Respir Res. 2014; 15:109. PMC: 4243719. DOI: 10.1186/s12931-014-0109-y. View

Lenz A, Jorens P, Meyer B, De Backer W, Van Overveld F, Bossaert L . Oxidatively modified proteins in bronchoalveolar lavage fluid of patients with ARDS and patients at-risk for ARDS. Eur Respir J. 2000; 13(1):169-74. DOI: 10.1034/j.1399-3003.1999.13a31.x. View

Collard H, Ryerson C, Corte T, Jenkins G, Kondoh Y, Lederer D . Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report. Am J Respir Crit Care Med. 2016; 194(3):265-75. DOI: 10.1164/rccm.201604-0801CI. View

Gordon S . Alternative activation of macrophages. Nat Rev Immunol. 2003; 3(1):23-35. DOI: 10.1038/nri978. View

Ooi G, Mok M, Tsang K, Wong Y, Khong P, Fung P . Interstitial lung disease in systemic sclerosis. Acta Radiol. 2003; 44(3):258-64. DOI: 10.1080/j.1600-0455.2003.00058.x. View

Cameli P, Bergantini L, Salvini M, Refini R, Pieroni M, Bargagli E . Alveolar concentration of nitric oxide as a prognostic biomarker in idiopathic pulmonary fibrosis. Nitric Oxide. 2019; 89:41-45. DOI: 10.1016/j.niox.2019.05.001. View

Naito Y, Takagi T, Higashimura Y . Heme oxygenase-1 and anti-inflammatory M2 macrophages. Arch Biochem Biophys. 2014; 564:83-8. DOI: 10.1016/j.abb.2014.09.005. View

Schupp J, Binder H, Jager B, Cillis G, Zissel G, Muller-Quernheim J . Macrophage activation in acute exacerbation of idiopathic pulmonary fibrosis. PLoS One. 2015; 10(1):e0116775. PMC: 4295887. DOI: 10.1371/journal.pone.0116775. View

Raghu G, Remy-Jardin M, Myers J, Richeldi L, Ryerson C, Lederer D . Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2018; 198(5):e44-e68. DOI: 10.1164/rccm.201807-1255ST. View

10.

Hara Y, Shinkai M, Taguri M, Nagai K, Hashimoto S, Kaneko T . ELISA Development for Serum Hemeoxygenase-1 and Its Application to Patients with Acute Respiratory Distress Syndrome. Can Respir J. 2018; 2018:9627420. PMC: 5932439. DOI: 10.1155/2018/9627420. View

11.

Travis W, Costabel U, Hansell D, King Jr T, Lynch D, Nicholson A . An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2013; 188(6):733-48. PMC: 5803655. DOI: 10.1164/rccm.201308-1483ST. View

12.

Kubo K, Azuma A, Kanazawa M, Kameda H, Kusumoto M, Genma A . Consensus statement for the diagnosis and treatment of drug-induced lung injuries. Respir Investig. 2013; 51(4):260-77. DOI: 10.1016/j.resinv.2013.09.001. View

13.

Murohashi K, Hara Y, Aoki A, Matsumura M, Kataoka T, Okudela K . Diffuse alveolar hemorrhage complicating acute exacerbation of IPF. Respir Med Case Rep. 2020; 29:101022. PMC: 7016274. DOI: 10.1016/j.rmcr.2020.101022. View

14.

Takahashi H, Fujishima T, Koba H, Murakami S, Kurokawa K, Shibuya Y . Serum surfactant proteins A and D as prognostic factors in idiopathic pulmonary fibrosis and their relationship to disease extent. Am J Respir Crit Care Med. 2000; 162(3 Pt 1):1109-14. DOI: 10.1164/ajrccm.162.3.9910080. View

15.

Takahashi H, Shiratori M, Kanai A, Chiba H, Kuroki Y, Abe S . Monitoring markers of disease activity for interstitial lung diseases with serum surfactant proteins A and D. Respirology. 2006; 11 Suppl:S51-4. DOI: 10.1111/j.1440-1843.2006.00809.x. View

16.

Simon-Blancal V, Freynet O, Nunes H, Bouvry D, Naggara N, Brillet P . Acute exacerbation of idiopathic pulmonary fibrosis: outcome and prognostic factors. Respiration. 2011; 83(1):28-35. DOI: 10.1159/000329891. View

17.

Hosseinzadeh A, Javad-Moosavi S, Reiter R, Yarahmadi R, Ghaznavi H, Mehrzadi S . Oxidative/nitrosative stress, autophagy and apoptosis as therapeutic targets of melatonin in idiopathic pulmonary fibrosis. Expert Opin Ther Targets. 2018; 22(12):1049-1061. DOI: 10.1080/14728222.2018.1541318. View

18.

Hara Y, Oshima Y, Tagami Y, Aoki A, Fujii H, Izawa A . Clinical importance of serum heme oxygenase-1 measurement in patients with acute exacerbation of idiopathic pulmonary fibrosis triggered by coronavirus disease 2019. Respir Med Case Rep. 2022; 36:101615. PMC: 8858429. DOI: 10.1016/j.rmcr.2022.101615. View

19.

Hyzy R, Huang S, Myers J, Flaherty K, Martinez F . Acute exacerbation of idiopathic pulmonary fibrosis. Chest. 2007; 132(5):1652-8. DOI: 10.1378/chest.07-0299. View

20.

Hara Y, Nakashima K, Nagasawa R, Murohashi K, Tagami Y, Aoki A . Heme Oxygenase-1 in Patients With Interstitial Lung Disease: A Review of the Clinical Evidence. Am J Med Sci. 2021; 362(2):122-129. DOI: 10.1016/j.amjms.2021.02.009. View